LC-MS/MS vs Immunoassays: Accuracy Differences in Testosterone Measurement
LC-MS/MS is significantly more accurate than immunoassays for measuring testosterone, particularly at low concentrations (<3.47 nmol/L or <100 ng/dL), where immunoassays systematically overestimate values and show unacceptable variability. 1
Key Accuracy Differences by Concentration Range
At Low Testosterone Levels (Women, Children, Castrated Patients)
The accuracy gap between methods is most pronounced at low concentrations:
- Immunoassays show considerable dispersal at concentrations typical of women, with variation due to both kit differences and poor precision at these levels 2
- All five tested immunoassays overestimated testosterone in women and children compared to LC-MS/MS, with positive mean differences across all methods 3
- In castrated prostate cancer patients, immunoassays measured mean testosterone at 0.672 ± 0.359 nM versus 0.461 ± 0.541 nM by mass spectrometry (P < 0.0001), resulting in 22.1% false "breakthrough" diagnoses versus 13.1% by LC-MS/MS 4
- Over 60% of samples with testosterone <3.47 nmol/L showed inaccurate results with immunoassays in both directions compared to LC-MS/MS 5
At Normal Male Range
The methods show better concordance but still significant variability:
- Most immunoassays yield values lower than GC-MS (the reference method related to LC-MS/MS), though concordance improves at male-range concentrations with less heterogeneity 2
- When 1,133 laboratories measured the same hypogonadal male sample using 14 different assays, values ranged from 45 to 365 ng/dL (1.6 to 12.7 nmol/L) 6
- Individual immunoassay biases vary: DPC Immulite showed mean difference of -90 ± 9 ng/dL (underestimation), while Bayer Centaur showed +99 ± 11 ng/dL (overestimation) across wide ranges 5
- Over 60% of samples in the adult male range measured by most methods fell within ±20% of LC-MS/MS values 5
Specific Performance Metrics
Functional Sensitivity
Functional sensitivity at 20% CV varies dramatically between immunoassays:
- ARCHITECT: 0.14 nmol/L
- Centaur: 1.23 nmol/L
- DxI: 0.36 nmol/L
- E170: 0.77 nmol/L
- IMMULITE: 3.49 nmol/L
LC-MS/MS achieves lower limits of quantitation (LLOQ) of 0.03 nmol/L, far superior to any immunoassay 7, 8
Method Comparison Data
In preterm infants, the difference is stark:
- Males: ECLIA median 1.10 ng/mL (IQR 0.90-2.69) vs LC-MS/MS 0.210 ng/mL (IQR 0.164-0.327)
- Females: ECLIA median 0.95 ng/mL (IQR 0.71-1.18) vs LC-MS/MS 0.026 ng/mL (IQR 0.0112-0.0526)
- Correlation was weak (ρ < 0.5), with LC-MS/MS showing superior diagnostic accuracy (AUC 0.96 vs 0.715) 9
Clinical Implications
When LC-MS/MS is Essential
Use LC-MS/MS for:
- Women with suspected hyperandrogenism
- Children and adolescents
- Castrated prostate cancer patients monitoring treatment
- Any testosterone value <3.47 nmol/L (<100 ng/dL)
- Confirming borderline results from immunoassays
When Immunoassays Are Acceptable
Immunoassays can distinguish eugonadal from hypogonadal adult males if laboratory-specific reference ranges are established and values are clearly in the normal male range (>12 nmol/L) 5, 10
Critical Pitfalls
Avoid these common errors:
- Never rely on immunoassay results <3.47 nmol/L without LC-MS/MS confirmation 3, 5
- Do not assume all immunoassays perform equally—functional sensitivity varies 25-fold between platforms 7
- Beware of false "castration failure" in prostate cancer patients—50% of immunoassay values ≥0.7 nM measured <0.7 nM by mass spectrometry 4
- Immunoassays are unreliable for free testosterone measurement regardless of concentration 1
Guideline Recommendations
The 2026 EAU guidelines explicitly state that LC-MS/MS is considered the reference method for total testosterone, though high cost limits routine use 1. The 2018 Endocrine Society guidelines recommend using CDC-certified assays or those verified by accuracy-based external quality control programs, acknowledging that liquid chromatography-tandem mass spectrometry generally offers higher specificity, sensitivity, and precision, especially in the low range 6.
For optimal clinical practice: measure testosterone by LC-MS/MS when diagnostic accuracy is critical, particularly at low concentrations; use only high-quality, validated immunoassays with known performance characteristics for routine screening in adult males; and always confirm borderline or unexpected immunoassay results with LC-MS/MS before making treatment decisions.